• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

    12/3/24 8:48:49 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AXDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PATIENCE JOHN

    (Last) (First) (Middle)
    C/O ACCELERATE DIAGNOSTICS, INC.
    3950 S. COUNTRY CLUB ROAD, SUITE 470

    (Street)
    TUCSON AZ 85714

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Accelerate Diagnostics, Inc [ AXDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/03/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/03/2024 P 200,000(1) A $1.57 653,224 I By John Patience Living Trust dated 7/23/1993(2)
    Common Stock 3,941 I By IRA
    Common Stock 214,046 I By Patience Enterprises LP(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction.
    2. The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
    3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
    /s/ David Patience, attorney-in-fact 12/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXDX

    DatePrice TargetRatingAnalyst
    3/9/2022$5.00Buy → Hold
    Craig-Hallum
    More analyst ratings

    $AXDX
    Financials

    Live finance-specific insights

    See more
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

      TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also

      1/10/25 4:05:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      12/5/24 5:13:13 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Accelerate Diagnostics Inc.

      SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

      11/14/24 3:24:23 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      8/12/24 5:01:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Leadership Updates

    Live Leadership Updates

    See more

    $AXDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

      TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur

      3/14/23 8:33:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

      TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our

      3/8/23 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      12/3/24 8:48:49 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Strobeck Matthew bought 100,000 shares (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:12:05 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Francesconi Louise bought 13,333 shares, increasing direct ownership by 176% to 20,927 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:11:07 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Accelerate Diagnostics downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00

      3/9/22 8:31:56 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

      TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process. Accelerate has filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without material disruption to their ordinary course o

      5/8/25 9:00:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    SEC Filings

    See more
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/28/25 4:10:50 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.

      NT 10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/16/25 5:27:55 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/12/25 4:16:21 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Shalhoub Paul Vincent

      3 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      5/1/25 6:40:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:34:08 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:32:39 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials